Intercure Ltd Dossier
Qualitative Analysis
Business overview
InterCure Ltd. (doing business as Canndoc) is the leading, profitable, and fastest-growing medical cannabis company operating outside of North America. Headquartered in Herzliya, Israel, and dual-listed on the NASDAQ and the Tel Aviv Stock Exchange (TASE) under the ticker INCR, the company operates a highly vertically integrated "seed-to-sale" model. Through its wholly owned subsidiary Canndoc, InterCure is Israel's largest licensed producer of pharmaceutical-grade, GMP-certified medical cannabis products. The company leverages a robust distribution network, including its proprietary Givol pharmacy chain, and maintains exclusive strategic partnerships with elite global cannabis brands such as Cookies, Tilray, Organigram, and Charlotte's Web to supply patients in Israel, Germany, and other international markets.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Rebuilding and expanding the state-of-the-art Nir Oz cultivation and manufacturing facility, which was severely damaged during the October 7th terror attacks.
Expected impact: Restores full domestic production capacity, enabling the company to return to pre-war growth and profitability rates.
Expansion of the company's European footprint by launching Cookies Corners licensed pharmacies in major German cities and introducing premium branded products.
Expected impact: Establishes InterCure as a leading international pharmaceutical cannabis platform in Europe's fastest-growing medical market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Secures exclusive brand partnerships, advanced technology platforms, and a robust distribution network to accelerate InterCure's global expansion.
Financial impact: Anticipated to generate over NIS 30 million in revenue during the second half of 2026 and be accretive within the first year.
Strategic Partnerships
High. Expands InterCure's European footprint by establishing Cookies Corners licensed pharmacies in 8 major German cities and launching next-generation branded products [2.1.1].
Terms: Multi-year exclusive licensing and distribution agreement.
High. Enhances InterCure's research and pharmaceutical capabilities, formalizing joint R&D of evidence-based cannabis therapeutics and supporting its positioning in the U.S. market.
Terms: Acquisition of a 28% ownership stake on a fully diluted basis with an exclusive path to increase holdings to 51% within two years.
Medium. Strengthens InterCure's global brand portfolio and premium medical cannabis offerings.
Terms: Exclusive brand partnership and genetics licensing.